CD4 and cancer: Additionally, a pan-cancer surge in CD4+ interferon gamma (IFNG+) T follicular helper (Tfh)/Th1 cells, CD8+ Tc17 cells, and mucosal-associated invariant T cells was noted post ICB treatment (Figures S2A and S2B).